Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia
Identifieur interne : 001373 ( Istex/Curation ); précédent : 001372; suivant : 001374Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia
Auteurs : Terence K. Y. Lai [Canada] ; Philip Seeman [Canada] ; Fang Liu [Canada]Source :
- Synapse [ 0887-4476 ] ; 2012-03.
English descriptors
- KwdEn :
Abstract
The long‐term use of many antipsychotic medications carries a risk of tardive dyskinesia in a small proportion of patients. Although metoclopramide is an antipsychotic at high doses, this drug is more commonly used at low daily doses to accelerate stomach movement of food. Because prolonged use of metoclopramide has also been associated with tardive dyskinesia, this drug is convenient to study to examine the possible basis of tardive dyskinesia. Previous work proposed that antipsychotics accumulated in the melanin granules of the human substantia nigra, ultimately building up to high concentrations that could disrupt cell membranes of nigral neurons. While previous work demonstrated the accumulation of metoclopramide in postmortem human nigral tissue, it remained to be tested whether high concentrations of metoclopramide would actually disrupt cell membranes. Therefore, the present work examined whether metoclopramide could disrupt cell membranes, using human erythrocytes directly exposed to various concentrations of metoclopramide in vitro. It was found that metoclopramide caused disruption of the red cells starting at a threshold of 1 mM, which would result in ∼280 μmoles of metoclopramide per kilogram of dry red cell membranes. However, the nonspecific adsorption of metoclopramide to human substantia nigra is ∼23 μmol/kg of dry solids (measured at the clinical spinal fluid concentration of metoclopramide). Therefore, the membrane‐lytic concentration of metoclopramide is only about 12 times higher than that after a single exposure of the drug to the nigral tissue. Hence, metoclopramide accumulation in the substantia nigra over a matter of months may lead to nigral neuron damage. Synapse, 2012. © 2011 Wiley Periodicals, Inc.
Url:
DOI: 10.1002/syn.21504
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001373
Links to Exploration step
ISTEX:81863FAAD26024D36B1A1169200BA0AD59D74794Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia</title><author><name sortKey="Lai, Terence K Y" sort="Lai, Terence K Y" uniqKey="Lai T" first="Terence K. Y." last="Lai">Terence K. Y. Lai</name><affiliation wicri:level="1"><mods:affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8</wicri:regionArea></affiliation></author><author><name sortKey="Seeman, Philip" sort="Seeman, Philip" uniqKey="Seeman P" first="Philip" last="Seeman">Philip Seeman</name><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario M5P 3L6, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, University of Toronto, Toronto, Ontario M5P 3L6</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario M5P 3L6, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, University of Toronto, Toronto, Ontario M5P 3L6</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto, Ontario M5P 3L6, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto, Ontario M5P 3L6</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Fang" sort="Liu, Fang" uniqKey="Liu F" first="Fang" last="Liu">Fang Liu</name><affiliation wicri:level="1"><mods:affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:81863FAAD26024D36B1A1169200BA0AD59D74794</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/syn.21504</idno><idno type="url">https://api-v5.istex.fr/document/81863FAAD26024D36B1A1169200BA0AD59D74794/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001373</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001373</idno><idno type="wicri:Area/Istex/Curation">001373</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia</title><author><name sortKey="Lai, Terence K Y" sort="Lai, Terence K Y" uniqKey="Lai T" first="Terence K. Y." last="Lai">Terence K. Y. Lai</name><affiliation wicri:level="1"><mods:affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8</wicri:regionArea></affiliation></author><author><name sortKey="Seeman, Philip" sort="Seeman, Philip" uniqKey="Seeman P" first="Philip" last="Seeman">Philip Seeman</name><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario M5P 3L6, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, University of Toronto, Toronto, Ontario M5P 3L6</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, University of Toronto, Toronto, Ontario M5P 3L6, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, University of Toronto, Toronto, Ontario M5P 3L6</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto, Ontario M5P 3L6, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, University of Toronto, 260 Heath St., West, Suite 605, Toronto, Ontario M5P 3L6</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Fang" sort="Liu, Fang" uniqKey="Liu F" first="Fang" last="Liu">Fang Liu</name><affiliation wicri:level="1"><mods:affiliation>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario M5T 1R8</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Synapse</title><title level="j" type="abbrev">Synapse</title><idno type="ISSN">0887-4476</idno><idno type="eISSN">1098-2396</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-03">2012-03</date><biblScope unit="volume">66</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="273">273</biblScope><biblScope unit="page" to="276">276</biblScope></imprint><idno type="ISSN">0887-4476</idno></series><idno type="istex">81863FAAD26024D36B1A1169200BA0AD59D74794</idno><idno type="DOI">10.1002/syn.21504</idno><idno type="ArticleID">SYN21504</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0887-4476</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>antipsychotics</term><term>erythrocytes</term><term>haloperidol</term><term>metoclopramide</term><term>red cell membrane</term><term>schizophrenia</term><term>tardive dyskinesia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The long‐term use of many antipsychotic medications carries a risk of tardive dyskinesia in a small proportion of patients. Although metoclopramide is an antipsychotic at high doses, this drug is more commonly used at low daily doses to accelerate stomach movement of food. Because prolonged use of metoclopramide has also been associated with tardive dyskinesia, this drug is convenient to study to examine the possible basis of tardive dyskinesia. Previous work proposed that antipsychotics accumulated in the melanin granules of the human substantia nigra, ultimately building up to high concentrations that could disrupt cell membranes of nigral neurons. While previous work demonstrated the accumulation of metoclopramide in postmortem human nigral tissue, it remained to be tested whether high concentrations of metoclopramide would actually disrupt cell membranes. Therefore, the present work examined whether metoclopramide could disrupt cell membranes, using human erythrocytes directly exposed to various concentrations of metoclopramide in vitro. It was found that metoclopramide caused disruption of the red cells starting at a threshold of 1 mM, which would result in ∼280 μmoles of metoclopramide per kilogram of dry red cell membranes. However, the nonspecific adsorption of metoclopramide to human substantia nigra is ∼23 μmol/kg of dry solids (measured at the clinical spinal fluid concentration of metoclopramide). Therefore, the membrane‐lytic concentration of metoclopramide is only about 12 times higher than that after a single exposure of the drug to the nigral tissue. Hence, metoclopramide accumulation in the substantia nigra over a matter of months may lead to nigral neuron damage. Synapse, 2012. © 2011 Wiley Periodicals, Inc.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001373 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001373 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:81863FAAD26024D36B1A1169200BA0AD59D74794
|texte= Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia
}}
| This area was generated with Dilib version V0.6.29. |  |